Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 7/20 | 0.47 |
| ▸ | CRBN | Q96SW2 | 7/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.41 |
| ▸ | BRD4 | O60885 | 7/20 | 0.38 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700857 | 0.91 | DDB1 (0.52) | DDB1CRBNCYP1A2CYP1B1TRIM24 | |
| SCHEMBL20845729 | 0.91 | DDB1 (0.52) | DDB1CRBNCYP1A2CYP1B1TRIM24 | |
| SCHEMBL26099776 | 0.81 | CRBN (0.61) | DDB1CRBNTRIM24 | |
| SCHEMBL26098753 | 0.81 | CRBN (0.61) | DDB1CRBNTRIM24 | |
| SCHEMBL20840210 | 0.81 | CRBN (0.60) | DDB1CRBNTRIM24 | |
| SCHEMBL20840314 | 0.81 | CRBN (0.60) | DDB1CRBNTRIM24 | |
| SCHEMBL20840317 | 0.81 | CRBN (0.60) | DDB1CRBNTRIM24 | |
| SCHEMBL20840207 | 0.81 | CRBN (0.60) | DDB1CRBNTRIM24 | |
| SCHEMBL30289415 | 0.80 | CRBN (0.62) | DDB1CRBNTRIM24 | |
| SCHEMBL31710038 | 0.79 | DDB1 (0.65) | DDB1CRBN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-02-09 | — | — | US | disclosed |
| US-11358948-B2 | CRBN ligands and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-14 | — | — | US | disclosed |
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2020-12-03 | — | — | US | disclosed |
| EP-3684366-A1 | CRBN LIGANDS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| WO-2019060693-A1 | CRBN LIGANDS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2019-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200377469-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885CYP1A2 4670/4885 |
| US-11358948-B2 | CRBN ligands and uses thereof | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885CYP1A2 4670/4885 |
| US-20230038512-A1 | CRBN LIGANDS AND USES THEREOF | CRBN, CRKL, ERBB3 | DDB1 304/4885CRBN 1/4885CYP1A2 4670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.